Table 1.
Demographic characteristics of the 12 studies that evaluated the association between PM2.5 and atherosclerosis.
First author and year | Outcome | Country | Study design | Data collection | N | Age, years Mean (SD/range) | % female | Data source | Baseline exposure level (mg/m3) |
---|---|---|---|---|---|---|---|---|---|
Adar 201312 a | CIMT | USA | Longitudinal | 2000–2005 | 5362 | 62 (10) | 52 | MESA | 16.6 |
Bauer 201013 | CIMT | Germany | Cross-sectional | 2000–2003 | 3380 | 60 (7.7) | 48 | HNRS | 16.8 |
Breton 201214 | CIMT | USA | Cross-sectional | 2007–2009 | 768 | 20 (1.5) | 59 | TROY | 15.7 |
Sun 201319 | CIMT | USA | Cross-sectional | 2000–2002 | 6256 | 62 (45–84) | 52 | MESA | 13.66 |
Diez Roux 2008 20a | CIMT | USA | Longitudinal | 2000–2002 | 5037 | 62 (45–84) | 53 | MESA | 16.7 |
Künzli 200521 | CIMT | USA | Cross-sectional | 1998–2003 | 798 | 59 (9.8) | 45 | VEAPS & BVAIT | 20.3 |
Lenters 201022 | CIMT | Netherlands | Longitudinal | 1999–2000 | 745 | 28 (0.9) | 53 | Not reported | 20.7 |
Künzli 201023a | CIMT | USA | Longitudinal | 1995–2007 | 1438 | 59 (9.6) | 63 | Five trialsb | 20.79 |
Allen 200924 a | AAC | USA | Cross-sectional | 2000–2002 | 1147 | 66 (9.4) | 50 | MESA | 15.8 |
Kälsch 201425 a | TAC | Germany | Cross-sectional | 2000–2003 | 4238 | 60 (7.8) | 50 | HNRS | 16.62 |
Sun 201319 | CAC | USA | Cross-sectional | 2000–2002 | 6256 | 62 (45–84) | 52 | MESA | 13.66 |
Diez Roux 2008 20a | CAC | USA | Cross-sectional | 200–2002 | 2149 | 62 (45–84) | 53 | MESA | 16.7 |
Hoffmann 200726 | CAC | Germany | Cross-sectional | 200–2003 | 4494 | 60 (7.8) | 51 | HNRS | 22.8 |
Hoffmann 200927 | ABI | Germany | Cross-sectional | 200–2003 | 4348 | 60 (7.8) | 51 | HNRS | 22.8 |
Diez Roux 2008 20 | ABI | USA | Cross-Sectional | 2000–2002 | 2149 | 62 (45–84) | 52 | MESA | 16.7 |
Study was excluded from the meta-analysis due to cohort overlap.
The five trials included in Kunzli 2010 are: B-vitamin Atherosclerosis Intervention Trial (BVAIT), Vitamin E Atherosclerosis Prevention Study (VEAPS), Estrogen in the Prevention of Atherosclerosis Trial (EPAT), Troglitazone Atherosclerosis Regression Trial (TART), Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART). PM2.5: particulate matter with aerodynamic diameter ≤ 2.5 μm; CIMT: carotid intima media thickness; CAC: coronary artery calcification; ABI: ankle-brachial index; HNRS: Heinz Nixdorf Recall Study; MESA: Multi-Ethnic Study of Atherosclerosis; TROY: Testing Responses On Youth study